Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP).
Saved in:
| Title: | Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). |
|---|---|
| Authors: | Derman BA; Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA. bderman@bsd.uchicago.edu., Major A; Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA., Cooperrider J; Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA., Jiang K; Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA., Ramsland A; Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA., Karrison T; Department of Public Health Sciences, University of Chicago, Chicago, IL, USA., Kubicki T; Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA., Jakubowiak AJ; Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA. |
| Source: | Blood cancer journal [Blood Cancer J] 2024 Oct 07; Vol. 14 (1), pp. 170. Date of Electronic Publication: 2024 Oct 07. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
